The pathology of pituitary adenomas from a clinical perspective

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 105-116

  Dworakowska, Dorota ^a,b,c   Korbonits, Marta ^a   Aylwin, Simon ^b   McGregor, Alan ^b   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Molecular Alteration; Pathophysiology; Pituitary Adenoma; Review

Indexed keywords

FIBROBLAST GROWTH FACTOR; KI 67 ANTIGEN; PROTEIN P53; ZINC FINGER PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GNAS PROTEIN, HUMAN; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR PROTEIN;

ALBRIGHT SYNDROME; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CARNEY COMPLEX; CHROMOSOMAL INSTABILITY; FAMILIAL ISOLATED PITUITARY ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; REVIEW;

CARNEY COMPLEX; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FIBROBLAST GROWTH FACTORS; FIBROUS DYSPLASIA, POLYOSTOTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 79955963364     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s136     Document Type: Article

References (105)

1. B. W. Scheithauer, T. A. Gaffey, R. V. Lloyd, T. J. Sebo, K. T. Kovacs, E. Horvath, O. Yapicier, W. F. Young, Jr., F. B. Meyer, T. Ku roki, D. L. Riehle andE. R. Laws, Jr.: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59, 341-53; discussion 341-53 (2006)
2. S. Ezzat, S. L. Asa, W. T. Couldwell, C. E. Barr, W. E. Dodge, M. L. Vance andI. E. McCutcheon: The prevalence of pituitary adenomas: a systematic review. Cancer 101, 613-9 (2004) (Pubitemid 38970613)
3. A. F. Daly, M. C. Burlacu, E. Livadariu andA. Beckers: The epidemiology and management of pituitary incidentalomas. Horm Res 68 Suppl 5, 195-8 (2007)
4. A. Fernandez, N. Karavitaki andJ. A. Wass: Prevalence o f pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72, 377-82
5. A. F. Daly, M. A. Tichomirowa andA. Beckers: The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23, 543-54 (2009)
6. J. Lindholm, S. Juul, J. O. Jorgensen, J. Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jorgensen, M. Kos teljanetz, L. Kristensen, P. Laurberg, K. Schmidt andJ. Weeke: Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86, 117-23 (2001) (Pubitemid 32111743)
7. A. Levy: Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin North Am 37, 23- 50, vii (2008)
8. P. L. Hanson, S. J. Aylwin, J. P. Monson andJ. M. Burrin: FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. Eur J Endocrinol 152, 363-70 (2005) (Pubitemid 40439488)
9. J. M. Alexander, B. M. Biller, H. Bikkal, N. T. Zervas, A. Arnold andA. Klibanski : Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86, 336-40 (1990) (Pubitemid 20227010)
10. S. A. Boikos andC. A. Stratakis: Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum Mol Genet 16 Spec No 1, R80-7 (2007) (Pubitemid 47241846)
11. M. Gueorguiev andA. B. Grossman: Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary (2008)
12. A. Levy andS. Lightman: Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 24, 94-127 (2003) (Pubitemid 36581937)
13. A. Beckers andA. F. Daly: The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 157, 371-82 (2007) (Pubitemid 350018439)
14. A. Karhu andL. A. Aaltonen: Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum Mol Genet 16 Spec No 1, R73-9 (2007) (Pubitemid 47241845)
15. A. Horvath andC. A. Stratakis: Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune- Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. R ev Endocr Metab Disord 9, 1-11 (2008)
16. M. F. Keil andC. A. Stratakis: Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 8, 563-74 (2008) (Pubitemid 351551009)
17. D. Dworakowska andA. B. Grossman: The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23, 525-41 (2009)
18. N. S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw a ndM. J. Atkinson: Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103, 15558-63 (2006) (Pubitemid 44625631)
19. O. Vierimaa, M. Georgitsi, R. Lehtonen, P. Vahteristo, A. Kokko, A. Raitila, K. Tuppurainen, T. M. Ebeling, P. I. Salmela, R. Paschke, S. Gundogdu, E. De Menis, M. J. Makinen, V. Launonen, A. Karhu andL. A. Aaltonen: Pituitary adenoma predisposi tion caused by germline mutations in the AIP gene. Science 312, 1228-30 (2006) (Pubitemid 43801151)
20. S. Igreja, H. S. Chahal, S. A. Akker, M. Gueorguiev, V. Popovic, S. Damjanovic, J. A. Wass, R. Quinton , A. B. Grossman andM. Korbonits: Assessment of p27 (cyclindependent kinase inhibitor 1B) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) ( 2008)
21. C. A. Leontiou, M. Gueorguiev, J. van der Spuy, R. Quinton, F. Lolli, S. Hassan, H. S. Chahal, S. C. Igreja, S. Jordan, J. Rowe, M. Stolbrink, H. C. Christian, J. Wray, D. Bishop-Bailey, D. M. Berney, J. A. Wass, V. Popovic, A. Ribeiro-Oliveira, Jr., M. R. Gadelha, J. P. Monson, S. A. Akker, J. R. Davis, R. N. Clayton, K. Yoshimoto, T. Iwata, A. Matsuno, K. Eguchi, M. Musat, D. Flanagan, G. Peters, G. B. Bolger, J. P. Chapple, L. A. Frohman, A. B. Grossman andM. Korbonits: The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J C lin Endocrinol Metab 93, 2390-401 (2008) (Pubitemid 351831563)
22. A. F. Daly, J. F. Vanbellinghen, S. K. Khoo, M. L. Jaffrain-Rea, L. A. Naves, M. A. Guitelman, A. Murat, P. Emy, A. P. Gimenez-Roqueplo, G. Tamburrano, G. Raverot, A. Barlier, W. De Herder, A. Penfornis, E. Ciccarelli, B. Estour, P. Lecomte, B. Gatta, O. Chabre, M. I. Sabate, X. Bertagna, N. Garcia Basavilbaso, G. Stalldecker, A. Cola o , P. Ferolla, J. L. Wemeau, P. Caron, J. L. Sadoul, A. Oneto, F. Archambeaud, A. Calender, O. Sinilnikova, C. F. Montanana, F. Cavagnini, V. Hana, A. Solano, D. Delettieres, D. C. Luccio-Camelo, A. Basso, V. Rohmer, T. Brue, V. Bours, B. T. Teh andA. Beckers: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92, 18 91-6 (2007) (Pubitemid 46997206)
23. D. C. Luccio-Camelo, K. N. Une, R. E. Ferreira, S. K. Khoo, R. Nickolov, M. D. Bronstein, M. Vaisman, B. T. Teh, L. A. Frohman, B. B. Mendonca andM. R. Gadelha: A meiotic recomb ination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 150, 643-8 (2004) (Pubitemid 38786533)
24. A. F. Daly, M. L. Jaffrain-Rea, A. Ciccarelli, H. Valdes-Socin, V. Rohmer, G. Tamburrano, C. Borson- Chazot, B. Estour, E. Ciccarelli, T. Brue, P. Ferolla, P. Emy, A. Colao, E. De Menis, P. Lecomte, F. Penfornis, B. Delemer, J. Bertherat, J. L. Wemeau, W. De Herder, F. Archambeaud, A. Stevenaert, A. Calender, A. Murat, F. Cavagnini andA. Beckers: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91, 3316-23 (2006) (Pubitemid 44402097)
25. H. S. Chahal, J. P. Chapple, L. A. Frohman, A. B. Grossman, M. Korbonits: Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas. Trends Endocrinol Metab (2010) in press
26. S. O. Akintoye, C. Chebli, S. Booher, P. Feuillan, H. Kushner, D. Leroith, N. Cherman, P. Bianco, S. Wientroub, P. G. Robey andM. T. Collins: Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 87, 5104-12 (2002) (Pubitemid 35316352)
27. L. Cuttler, J. A. Jackson, M. Saeed uz-Zafar, L. L. Levitsky, R. C. Mellinger andL. A. Frohman: Hypersecretion of growth horm one and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 68, 1148-54 (1989) (Pubitemid 19144745)
28. A. Spada, M. Arosio, D. Bochicchio, N. Bazzoni, L. Vallar, M. Bassetti andG. Faglia: Clinical, biochem ical, and morphological correlates in patients bearing growth hormonesecreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71, 1421-6 (1990) (Pubitemid 120032754)
29. A. Lania, G. Mantovani andA. Spada: Genetics of pituitary tumors: Focus on G-protein mutations. Exp Biol Med (Maywood) 228, 1004-17 (2003) (Pubitemid 37222168)
30. A. G. Lania, S. Ferrero, R. Piv onello, G. Mantovani, E. Peverelli, A. Di Sarno, P. Beck-Peccoz, A. Spada andA. Colao: Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95, 13-7
31. J. R. Burgess, T. M. Greenaway andJ. J. Shepherd: Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 243, 465-70 (1998) (Pubitemid 28312242)
32. J. Jagannathan, A. S. Dumont, D. M. Prevedello, B. Lopes, R. J. Oskouian, J. A. Jane, Jr. andE. R. Laws, Jr.: Genetics of pituitary adenomas: current theories and future implications. Neurosurg Focus 19, E4 (2005)
33. J. Trouillas, F. Labat-Moleur, N. Sturm, M. Kujas, M. F. Heymann, D. Figarella-Branger, M. Patey, M. Mazucca, E. Decullier, B. Verges, O. Chabre andA. Calender: P ituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32, 534-43 (2008) (Pubitemid 351458295)
34. W. E. Farrell, D. J. Simpson, J. Bicknell, J. L. Magnay, E. Kyrodimou, R. V. Thakker andR. N. Clayton: Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br J Cancer 80, 44-50 (1 999) (Pubitemid 29210086)
35. J. Poncin, A. Stevenaert andA. Beckers: Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 140, 573-6 (1999) (Pubitemid 29314720)
36. P. L. Dahia, R. C. Aguiar, J. Honegger, R. Fahlbush, S. Jordan, D. G. Lowe, X. Lu, R. N. Clayton, G. M. Besser andA. B. Grossman: Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16, 69-76 (1998) (Pubitemid 28043509)
37. N. Hai, N. Aoki, A. Shimatsu, T. Mori andS. Kosugi: Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analys is of 20 Japanese sporadic cases with MEN1. Clin Endocrinol (Oxf) 52, 509-18 (2000) (Pubitemid 30249820)
38. M. Georgitsi, A. Raitila, A. Karhu, R. B. van der Luijt, C. M. Aalfs, T. Sane, O. Vierimaa, M. J. Mak inen, K. Tuppurainen, R. Paschke, O. Gimm, C. A. Koch, S. Gundogdu, A. Lucassen, M. Tischkowitz, L. Izatt, S. Aylwin, G. Bano, S. Hodgson, E. De Menis, V. Launonen, P. Vahteristo andL. A. Aaltonen: Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 92, 3321-5 (2007) (Pubitemid 47236408)
39. R. V. Lloyd, L. Jin, X. Qian andE. Kulig: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150, 401-7 (1997) (Pubitemid 27073769)
40. K. Lidhar, M. Korbonits, S. Jordan, Z. Khalimova, G. Kaltsas, X. Lu, R. N. Clayton, P. J. Jenkins, J. P. Monson, G. M. Besser, D. G. Lowe andA. B. Grossman: Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 84, 3823-30 (1999) (Pubitemid 30645248)
41. T. A. Milne, C. M. Hughes, R. Lloyd, Z. Yang, O. Rozenblatt-Rosen, Y. Dou, R. W. Schnepp, C. Krankel, V. A. Livolsi, D. Gibbs, X. Hua, R. G. Roeder, M. Meyerson andJ. L. Hess: Menin and MLL cooperatively regu late expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 102, 749-54 (2005) (Pubitemid 40282737)
42. M. Drosten, G. Hilken, M. Bockmann, F. Rodicker, N. Mise, A. N. Cranston, U. Dahmen, B. A. Ponder andB. M. Putzer: Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 96, 1231-9 (2004) (Pubitemid 39232714)
43. S. K. Kolluri, C. Weiss, A. Koff andM. Gottlich er: p27 (Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 13, 1742-53 (1999) (Pubitemid 29325878)
44. L. S. Kirschner, J. A. Carney, S. D. Pack, S. E. Taymans, C. Giatzakis, Y. S. Cho, Y. S. Cho-Chung andC. A. Stratakis: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in pati ents with the Carney complex. Nat Genet 26, 89-92 (2000)
45. I. Bossis, A. Voutetakis, L. Matyakhina, S. Pack, M. Abu-Asab, I. Bourdeau, K. J. Griffin, N. Courcoutsakis, S. Stergiopoulos , D. Batista, M. Tsokos andC. A. Stratakis: A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 41, 596-600 (2004) (Pubitemid 39061265)
46. Z. Yin, L. Williams-Simons, A. F. Parlow, S. Asa andL. S. Kirschner: Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol 22, 380-7 (2008) (Pubitemid 351185937)
47. G. A. Kaltsas, B. Kola, N. Borboli, D. G. Morris, M. Gueorguiev, F. M. Swords, S. Czirjak, L. S. Kirschner, C. A. Stratakis, M. Korbonits andA. B. Grossman: Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 57, 443-8 (2002) (Pubitemid 35216295)
48. F. Sandrini, L. S. Kirschner, T. Bei, C. Farmakidis, J. Yasufuku-Takano, K. Taka no, T. R. Prezant, S. J. Marx, W. E. Farrell, R. N. Clayton, L. Groussin, J. Bertherat andC. A. Stratakis: PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carn ey complex. J Med Genet 39, e78 (2002)
49. M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M. J. Makinen, O. Vierimaa, R. Paschke, W. Saeger, R. B. van der Luijt, T. Sane, M. Robledo, E. De Menis, R. J. Weil, A. Wasik, G. Zielinski, O. Lucewicz, J. Lubinski, V. Launonen, P. Vahteristo andL. A. Aaltonen: Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon rec eptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 104, 4101-5 (2007) (Pubitemid 47181585)
50. J. L. Marlowe andA. Puga: Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 96, 1174-84 (2005) (Pubitemid 41681860)
51. D. Dworakowska and A. B. Grossman: Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer 16, 45-58 (2009)
52. S. L. Asa andS. Ezzat: The pathogenesis of pituitary tumours. Nat Rev Cancer 2, 836-49 (2002) (Pubitemid 37328902)
53. H. J. Karga, J. M. Alexander, E. T. Hedley-Whyte, A. Klibanski andJ. L. Jameson: Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74, 914-9 (1992)
54. V. Herman, N. Z. Drazin, R. Gonsky andS. Melmed: Molecular screening of pituitary adenomas for gene mutations and rearrangement s. J Clin Endocrinol Metab 77, 50-5 (1993) (Pubitemid 23206775)
55. M. D. Boggild, S. Jenkinson, M. Pistorello, M. Boscaro, M. Scanarini, P. McTernan, C. W. Perrett, R. V. Thakker andR. N. Clayton: Molecu lar genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 78, 387-92 (1994) (Pubitemid 24061758)
56. V. L. Cryns, J. M. Alexander, A. Klibanski andA. Arnold: The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 77, 644-6 (1993) (Pubitemid 23298641)
57. L. Pei, S. Melmed, B. Scheithauer, K. Kovacs, W. F. Benedict andD. Prager: Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggr essive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55, 1613-6 (1995)
58. Y. Tanizaki, L. Jin, B. W. Scheithauer, K. Kovacs, F. Roncaroli andR. V. Lloyd: P53 gene mutations in pituitary carcinomas. Endocr Pathol 18, 217-22 (2007)
59. L. Pei andS. Melmed: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11, 433-41 (1997) (Pubitemid 27147011)
60. F. Salehi, K. Kovacs, B. W. Scheithauer, R. V. Lloyd andM. Cusimano: Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 15, 721-43 (2008)
61. R. Bharadwaj andH. Yu: The spindle checkpoint, aneuploidy, and cancer. Oncogene 23, 2016-27 (2004) (Pubitemid 38496731)
62. H. Zou, T. J. McGarry, T. Bernal andM. W. Kirschner: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigene sis. Science 285, 418-22 (1999)
63. X. Zhang, G. A. Horwitz, A. P. Heaney, M. Nakashima, T. R. Prezant, M. D. Bronstein andS. Melmed: Pituitary tumor transforming gene (PTTG) expression in pituita ry adenomas. J Clin Endocrinol Metab 84, 761-7 (1999) (Pubitemid 29075718)
64. Z. Wang andS. Melmed: Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275, 7459-61 (2000) (Pubitemid 30159638)
65. K. Chamaon, E. Kirches, D. Kanakis, S. Braeuninger, K. Dietzmann andC. Mawrin: Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-ne oplastic astrocytes. Biochem Biophys Res Commun 331, 86-92 (2005) (Pubitemid 40545146)
66. D. Dworakowska, E. Wlodek, C. A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M. I. Goth, S. Grozinsky-Gla sberg, M. Gueorguiev, B. Kola, M. Korbonits andA. B. Grossman: Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16, 1329-38 (2009)
67. P. Rodriguez-Viciana, P. H. Warne, A. Khwaja, B. M. Marte, D. Pappin, P. Das, M. D. Waterfield, A. Ridley andJ. Downward: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-67 (1997) (Pubitemid 27220890)
68. A. Kauffmann-Zeh, P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffer, J. Downward andG. Evan: Suppression of c- Myc-induced apoptosis by Ra s signalling through PI (3)K and PKB. Nature 385, 544-8 (1997) (Pubitemid 27074674)
69. S. Volarevic andG. Thomas: Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65, 101-27 (2001)
70. Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing andY. Lu: Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 16, 301-10 (2009)
71. M. Musat, M. Korbonits, B. Kola, N. Borboli, M. R. Hanson, A. M. Nanzer, J. Grigson, S. Jordan, D. G. Morris, M. Gueorguiev, M. Coculescu, S. Basu andA. B. Grossman: Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 12, 423-33 (2005) (Pubitemid 40896456)
72. A. A. Adjei andM. Hidalgo: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23, 5386-403 (2005) (Pubitemid 46206992)
73. T. A. Haystead, P. Dent, J. Wu, C. M. Haystead andT. W. Sturgill: Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 306, 17-22 (1992)
74. Y. Terada, O. Nakashima, S. Inoshita, M. Kuwahara, S. Sasaki andF. Marumo: Mi togen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Nephrol Dial Transplant 14 Suppl 1, 45-7 (1999) (Pubitemid 29041837)
75. Y. Terada, S. Inoshita, O. Nakashima, M. Kuwahara, S. Sasaki andF. Marumo: Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney Int 56, 1258-61 (1999) (Pubitemid 29451224)
76. K. L. Guan: The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal 6, 581-9 (1994)
77. T. Joneson andD. Bar-Sagi: Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 75, 587-93 (1997) (Pubitemid 27373601)
78. I. Ewing, S. Pedder-Smith, G. Franchi, M. Ruscica, M. Emery, V. Vax, E. Garcia, S. Czirjak, Z. Hanzely, B. Kola, M. Korbonits andA. B. Grossman: A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66, 348-52 (2007) (Pubitemid 46239291)
79. N. A. Hibberts, D. J. Simpson, J. E. Bicknell, J. C. Broome, P. R. Hoban, R. N. Clayton andW. E. Farrell: Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 5, 2133-9 (1999) (Pubitemid 29399269)
80. S. Jordan, K. Lidhar, M. Korbonits, D. G. Lowe andA. B. Grossman: Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143, R1-6 (2000) (Pubitemid 30482213)
81. J. A. McCubrey, L. S. Steelman, S. L. Abrams, J. T. Lee, F. Chan g, F. E. Bertrand, P. M. Navolanic, D. M. Terrian, R. A. Franklin, A. B. D'Assoro, J. L. Salisbury, M. C. Mazzarino, F. Stivala andM. Libra: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation a nd drug resistance. Adv Enzyme Regul 46, 249-79 (2006) (Pubitemid 44301348)
82. M. Cakir andA. B. Grossman: Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin Ther Targets 13, 1121-34 (2009)
83. R. Gejman, B. Swearingen andE. T. Hedley-Whyte: Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39, 758-66 (2008) (Pubitemid 351601606)
84. T. W. Noh, H. J. Jeong, M. K. Lee, T. S. Kim, S. H. Kim andE. J. Lee: Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94, 4406-13 (2009)
85. Y. Ogawa, H. Ikeda andT. Tominaga: Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%. J Endocrinol Invest 32, 581-4 (2009)
86. A. B. Grossman: The molecular biology of pituitary tumors: a personal perspective. Pituitary 12, 265-70 (2009)
87. C. Lu, M. C. Willingham, F. Furuya andS. Y. Cheng: Activation of phosphatidylinositol 3-kinase sig naling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149, 3339-45 (2008) (Pubitemid 351919619)
88. J. J. An, S. R. Cho, D. W. Jeong, K. W. Park, Y. S. Ahn andJ. H. Baik: Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206, 49-62 (2003) (Pubitemid 37011252)
89. S. L. Fougner, J. Bollersl ev, F. Latif, J. K. Hald, T. Lund, J. Ramm-Pettersen andJ. P. Berg: Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Me tab 93, 1211-6 (2008) (Pubitemid 351519712)
90. C. P. Tanase, M. Neagu andR. Albulescu: Key signaling molecules in pituitary tumors. Expert Rev Mol Diagn 9, 859-77 (2009)
91. J. Bertherat, P. Chanson andM. Montminy: The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9, 777-83 (1995)
92. E. J. Lee, W. R. Duan, T. Kotlar andJ. L. Jameson: Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 142, 414-20 (2001) (Pubitemid 32183703)
93. M. Theodoropoulou, G. K. Stalla andD. Spengler: ZAC1 target genes and pituitary tumorigenesis. Mol Cell Endocrinol
94. M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez- Pereda, C. Erneux, T. Florio, U. Pagotto andG. K. Stalla: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66, 1576-82 (2006) (Pubitemid 43259940)
95. U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grubler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G. K. Stalla andD. Spengler: The expression of the antiproliferative gene ZAC is lost o r highly reduced in nonfunctioning pituitary adenomas. Cancer Res 60, 6794-9 (2000) (Pubitemid 32059140)
96. S. L. Fougner, T. Lekva, O. C. Borota, J. K. Hald, J. Bollerslev andJ. P. Berg: The Expression of E-Cadheri n in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response. J Clin Endocrinol Metab
97. A. L. Machado, P. Nomikos, F. Kiesewetter, R. Fahlbusch andM. Buchfelder: DNA -flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis. J Endocrinol Invest 28, 795-801 (2005) (Pubitemid 43162833)
98. M. Filippella, F. Galland, M. Kujas, J. Young, A. Faggiano, G. Lomba rdi, A. Colao, G. Meduri andP. Chanson: Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (O xf) 65, 536-43 (2006) (Pubitemid 44414280)
99. C. J. McCabe, K. Boelaert, L. A. Tannahill, A. P. Heaney, A. L. Stratford, J. S. Khaira, S. Hussain, M. C. Sheppard, J. A. Franklyn andN. J. Gittoes: Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87, 4238-44 (2002)
100. T. Minematsu, M. Suzuki, N. Sanno, S. Takekoshi, A. Teramoto andR. Y. Osamura: PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 17, 143-53 (2006) (Pubitemid 44965903)
101. C. J. Powers, S. W. McLeskey andA. Wellstein: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7, 165-97 (2000)
102. D. Givol andA. Yayon: Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 6, 3362-9 (1992) (Pubitemid 23007101)
103. S. Ezzat, H. S. Smyth, L. Ramyar andS. L. Asa: Heterogenous in vivo and in vitro expression of basic f ibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80, 878-84 (1995)
104. Z. R. Qian, T. Sano, S. L. Asa, S. Yamada, H. Horiguchi, T. Tashiro, C. C. Li, M. Hirokawa, K. Kovacs andS. Ezzat: Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adeno mas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89, 1904-11 (2004) (Pubitemid 38507952)
105. G. Raverot, A. Wierinckx, E. Dantony, C. Auger, G. Chapas, L. Villeneuve, T. Brue, D. Figarella-Branger, P. Roy, E. Jouanneau, M. Jan, J. Lachuer andJ. Trouillas: Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperat ive follow-up. J Clin Endocrinol Metab 95, 1708-16 (2010)